席少枝,尹彤,陈韵岱

• 1:中国人民解放军总医院心血管内科

摘要(Abstract)：

<正>随着新型抗栓药物和经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的进展,急性冠状动脉综合征(acute coronary syndrome,ACS)患者PCI术后缺血事件发生率显著降低,但是出血发生率明显上升,并且已经成为ACS患者PCI术后发生率最高的并发症之一[1]。近年来越来越多的研究证实,ACS患者PCI术后不同阶段(围

关键词(KeyWords)： 急性冠状动脉综合征;经皮冠状动脉介入治疗;抗栓治疗;出血风险;模型

Abstract:

Keywords:

基金项目(Foundation): “十三五”国家重点研发计划(2016):冠状动脉粥样硬化病变早期识别和风险预警的影像学评价体系研究(2016YFC1300300)

作者(Author): 席少枝,尹彤,陈韵岱

参考文献(References)：

• [1]Eikelboom JW,Mehta SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.Circulation,2006,114(8):774-782.
• [2]Baber U,Dangas G,Chandrasekhar J,et al.Time-Dependent Associations Between Actionable Bleeding,Coronary Thrombotic Events,and Mortality Following Percutaneous Coronary Intervention:Results From the PARIS Registry.JACC Cardiovasc Interv,2016,9(13):1349-1357.
• [3]Steg PG,Huber K,Andreotti F,et al.Bleeding in acute coronary syndromes and percutaneous coronary interventions:position paper by the Working Group on Thrombosis of the European Society of Cardiology.Eur Heart J,2011,32(15):1854-1864.
• [4]Brener SJ,Kirtane AJ,Stuckey TD,et al.The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention:The ADAPT-DES Study.JACC Cardiovasc Interv,2016,9(14):1450-1457.
• [5]Moscucci M,Fox KA,Cannon CP,et al.Predictors of major bleeding in acute coronary syndromes:the Global Registry of Acute Coronary Events(GRACE).Eur Heart J,2003,24(20):1815-1823.
• [6]Kinnaird TD,Stabile E,Mintz GS,et al.Incidence,predictors,and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions.Am J Cardiol,2003,92(8):930-935.
• [7]Feit F,Voeltz MD,Attubato MJ,et al.Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.Am J Cardiol,2007,100(9):1364-1369.
• [8]Ratib K,Mamas MA,Anderson SG,et al.Access site practice and procedural outcomes in relation to clinical presentation in 439,947 patients undergoing percutaneous coronary intervention in the United kingdom.JACC Cardiovasc Interv,2015,8(1 Pt A):20-29.
• [9]Numasawa Y,Kohsaka S,Ueda I,et al.Incidence and predictors of bleeding complications after percutaneous coronary intervention.J Cardiol,2017,69(1):272-279.
• [10]Genereux P,Giustino G,Witzenbichler B,et al.Incidence,Predictors,and Impact of Post-Discharge Bleeding Af ter Percutaneous Coronary Intervention,J Am Coll Cardiol,2015,66(9):1036-1045.
• [11]Baber U,Mehran R,Giustino G,et al.Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents:Risk Scores From PARIS.J Am Coll Cardiol,2016,67(19):2224-2234.
• [12]Valle JA,Shetterly S,Maddox TM,et al.Postdischarge Bleeding Af ter Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction:Insights From the HMO Research Network-Stent Registry.Circ Cardiovasc Interv,2016,9(6)pii:e003519.
• [13]Cuisset T,Deharo P,Quilici J,et al.Benefit of switching dual antiplatelet therapy after acute coronary syndrome:the TOPIC(timing of platelet inhibition after acute coronary syndrome)randomized study.Eur Heart J,2017,38(41):3070-3078.
• [14]Stone GW,Mc Laurin BT,Cox DA,et al.Bivalirudin for patients with acute coronary syndromes.N Engl J Med,2006,355(21):2203-2216.
• [15]Kolh P,Windecker S,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur J Cardiothorac Surg,2014,46(4):517-592.
• [16]Roffi M,Patrono C,Collet JP,et al.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC).G Ital Cardiol(Rome),2016,17(10):831-872.
• [17]中华医学会心血管病学分会介入心脏病学组.中国经皮冠状动脉介入治疗指南(2016).中华心血管病杂志,2016,44(5):382-400
• [18]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Thorac Cardiovasc Surg,2016,152(5):1243-1275.
• [19]Redfors B,Kirtane AJ,Pocock SJ,et al.Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.J Am Coll Cardiol,2016,68(24):2608-2618.
• [20]Lopes RD,Subherwal S,Holmes DN,et al.The association of in-hospital major bleeding with short-,intermediate-,and longterm mortality among older patients with non-ST-segment elevation myocardial infarction.Eur Heart J,2012,33(16):2044-2053.
• [21]Amin AP,Wang TY,Mc Coy L,et al.Impact of Bleeding on Quality of Life in Patients on DAPT:Insights From TRANSLATEACS.J Am Coll Cardiol,2016,67(1):59-65.
• [22]Chandrasekhar J,Baber U,Sartori S,et al.Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention:Results from the PROMETHEUS study.Catheter Cardiovasc Interv,2017,89(4):629-637.
• [23]Alexopoulos D,Xanthopoulou I,Deftereos S,et al.Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention:1-year outcomes from the GReek Anti Plat Elet(GRAPE)Registry.J Thromb Haemost,2016,14(6):1146-1154.
• [24]Kazi DS,Leong TK,Chang TI,et al.Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention.J Am Coll Cardiol,2015,65(14):1411-1420.
• [25]Chhatriwalla AK,Amin AP,Kennedy KF,et al.Association between bleeding events and in-hospital mortality after percutaneous coronary intervention.JAMA,2013,309(10):1022-1029.
• [26]Mehran R,Baber U,Steg PG,et al.Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention(PARIS):2 year results from a prospective observational study.Lancet,2013,382(9906):1714-1722.
• [27]Mehta RH,Parsons L,Rao SV,et al.Association of bleeding and in-hospital mortality in black and white patients with st-segmentelevation myocardial infarction receiving reperfusion.Circulation,2012,125(14):1727-1734.
• [28]Fox KA,Carruthers K,Steg PG,et al.Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome?The global registry of acute coronary events.Eur Heart J,2010,31(6):667-675.
• [29]Doyle BJ,Rihal CS,Gastineau DA,et al.Bleeding,blood transfusion,and increased mortality after percutaneous coronary intervention:implications for contemporary practice.J Am Coll Cardiol,2009,53(22):2019-2027.
• [30]Kim P,Dixon S,Eisenbrey AB,et al.Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention.Clin Cardiol,2007,30(10Suppl 2):Ⅱ35-43.
• [31]Yatskar L,Selzer F,Feit F,et al.Access site hematoma requiring blood transf usion predicts mortality in patients undergoing percutaneous coronary intervention:data from the National Heart,Lung,and Blood Institute Dynamic Registry,Catheter Cardiovasc Interv,2007,69(7):961-966
• [32]Ndrepepa G,Berger PB,Mehilli J,et al.Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions:appropriateness of including bleeding as a component of a quadruple end point.J Am Coll Cardiol,2008,51(7):690-697.
• [33]Doyle BJ,Ting HH,Bell MR,et al.Major femoral bleeding complications after percutaneous coronary intervention:incidence,predictors,and impact on long-term survival among 17,901patients treated at the Mayo Clinic from 1994 to 2005.JACC Cardiovasc Interv,2008,1(2):202-209.
• [34]Zheng X,Curtis JP,Hu S,et al.Coronary Catheterization and Percutaneous Coronary Intervention in China:10-Year Results From the China PEACE-Retrospective Cath PCI Study.JAMA Internal Medicine,2016,176(4):512-521.
• [35]Lincoff AM,Kleiman NS,Kereiakes DJ,et al.Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization:REPLACE-2 randomized trial.JAMA,2004,292(6):696-703.
• [36]Lincoff AM,Bittl JA,Kleiman NS,et al.Comparison of bivalirudin versus heparin during percutaneous coronary intervention(the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events[REPLACE]-1trial).Am J Cardiol,2004,93(9):1092-1096.
• [37]Montalescot G,White HD,Gallo R,et al.Enoxaparin versus unf ractionated heparin in elective percutaneous coronary intervention.N Engl J Med,2006,355(10):1006-1017.
• [38]Stone GW,Bertrand M,Colombo A,et al.Acute Catheterization and Urgent Intervention Triage strateg Y(ACUITY)trial:study design and rationale.Am Heart J,2004,148(5):764-775.
• [39]Mehran R,Brodie B,Cox DA,et al.The Harmonizing Outcomes with Revasculari Zati ON and Stents in Acute Myocardial Infarction(HORIZONS-AMI)Trial:study design and rationale.Am Heart J,2008,156(1):44-56.
• [40]Mauri L,Kereiakes DJ,Normand SL,et al.Rationale and design of the dual antiplatelet therapy study,a prospective,multicenter,randomized,double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.Am Heart J,2010,160(6):1035-1041.
• [41]Pilgrim T,Heg D,Roffi M,et al.Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimuseluting stent f or percutaneous coronary revascularisation(BIOSCIENCE):a randomised,single-blind,non-inferiority trial.Lancet,2014,384(9960):2111-2122.
• [42]Raber L,Kelbaek H,Ostojic M,et al.Effect of biolimuseluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction:the COMFORTABLE AMI randomized trial.JAMA,2012,308(8):777-787.
• [43]Gwon HC,Hahn JY,Park KW,et al.Six-month versus12-month dual antiplatelet therapy after implantation of drugeluting stents:the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting(EXCELLENT)randomized,multicenter study.Circulation,2012,125(3):505-513.
• [44]Feres F,Costa RA,Abizaid A,et al.Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial.JAMA,2013,310(23):2510-2522.
• [45]Valgimigli M,Campo G,Monti M,et al.Short-versus longterm duration of dual-antiplatelet therapy after coronary stenting:a randomized multicenter trial.Circulation,2012,125(16):2015-2026.
• [46]Kim BK,Hong MK,Shin DH,et al.A new strategy for discontinuation of dual antiplatelet therapy:the RESET Trial(REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).J Am Coll Cardiol,2012,60(15):1340-1348.
• [47]Colombo A,Chieffo A,Frasheri A,et al.Second-generation drugeluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy:the SECURITY randomized clinical trial.J Am Coll Cardiol,2014,64(20):2086-2097.
• [48]Valgimigli M,Patialiakas A,Thury A,et al.Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.J Am Coll Cardiol,2015,65(8):805-815.
• [49]Hoekstra JW,Pollack CV Jr.,Roe MT,et al.Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department:the CRUSADE initiative.Acad Emerg Med,2002,9(11):1146-1155.
• [50]Bhatt DL,Roe MT,Peterson ED,et al.Utilization of early invasive management strategies for high-risk patients with nonST-segment elevation acute coronary syndromes:results from the CRUSADE Quality Improvement Initiative.JAMA,2004,292(17):2096-2104.
• [51]Nikolsky E,Mehran R,Dangas G,et al.Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.Eur Heart J,2007,28(16):1936-1945.
• [52]Montalescot G,Salette G,Steg G,et al.Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention.Int J Cardiol,2011,150(1):79-83.
• [53]Rao SV,Mc Coy LA,Spertus JA,et al.An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention:a report using an expanded bleeding definition from the National Cardiovascular Data Registry Cath PCI Registry.JACC Cardiovasc Interv,2013,6(9):897-904.
• [54]Brindis RG,Fitzgerald S,Anderson HV,et al.The American College of Cardiology-National Cardiovascular Data Registry(ACC-NCDR):building a national clinical data repository.J Am Coll Cardiol,2001,37(8):2240-2245.
• [55]Subherwal S,Bach RG,Chen AY,et al.Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction:the CRUSADE(Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines)Bleeding Score.Circulation,2009,119(4):1873-1882.
• [56]Mehran R,Pocock SJ,Nikolsky E,et al.A risk score to predict bleeding in patients with acute coronary syndromes.J Am Coll Cardiol,2010,55(23):2556-2566.
• [57]Mathews R,Peterson ED,Chen AY,et al.In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care:derivation and validation of a model from the ACTION Registry(R)-GWTG.Am J Cardiol,2011,107(8):1136-1143.
• [58]Abu-Assi E,Gracia-Acuna JM,Ferreira-Gonzalez I,et al.Evaluating the Performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines(CRUSADE)bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction.Circulation,2010,121(22):2419-2426.
• [59]Ariza-Sole A,Sanchez-Elvira G,Sanchez-Salado JC,et al.CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.Thromb Res,2013,132(6):652-658.
• [60]Abu-Assi E,Raposeiras-Roubin S,Lear P,et al.Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome.Eur Heart J Acute Cardiovasc Care,2012,1(3):222-231.
• [61]Flores-Rios X,Couto-Mallon D,Rodriguez-Garrido J,et al.Comparison of the performance of the CRUSADE,ACUITYHORIZONS,and ACTION bleeding risk scores in STEMI undergoing primary PCI:insights from a cohort of 1391 patients.Eur Heart J Acute Cardiovasc Care,2013,2(1):19-26.
• [62]Jinatongthai P,Khaisombut N,Likittanasombat K,et al.Use of the CRUSADE bleeding risk score in the prediction of major bleeding for patients with acute coronary syndrome receiving enoxaparin in Thailand.Heart Lung Circ,2014,23(11):1051-1058.
• [63]Kharchenko MS,Erlikh AD,Gratsianskii NA.Assessment of the prognostic value of the CRUSADE score in patients with acute coronary syndromes hospitalized in a noninvasive hospital.Kardiologiia,2012,52(8):27-32.
• [64]Taha S,D'Ascenzo F,Moretti C,et al.Accuracy of bleeding scores for patients presenting with myocardial infarction:a metaanalysis of 9 studies and 13 759 patients.Postepy Kardiol Interwencyjnej,2015,11(3):182-190.
• [65]Correia LC,Ferreira F,Kalil F,et al.Comparison of ACUITY and CRUSADE Scores in Predicting Major Bleeding during Acute Coronary Syndrome.Arq Bras Cardiol,2015,105(1):20-27.
• [66]Liu R,Lyu SZ,Zhao GQ,et al.Comparison of the performance of the CRUSADE,ACUITY-HORIZONS,and ACTION bleeding scores in ACS patients undergoing PCI:insights from a cohort of4939 patients in China.J Geriatr Cardiol,2017,14(2):93-99.
• [67]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32(23):2999-3054.
• [68]Peterson ED,Roe MT,Rumsfeld JS,et al.A call to ACTION(acute coronary treatment and intervention outcomes network):a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction.Circ Cardiovasc Qual Outcomes,2009,2(5):491-499.
• [69]Yeh RW,Secemsky EA,Kereiakes DJ,et al.Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.JAMA,2016,315(16):1735-1749.
• [70]Costa F,van Klaveren D,James S,et al.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT)score:a pooled analysis of individualpatient datasets from clinical trials.Lancet,2017,389(10073):1025-1034.
• [71]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361(11):1045-1057.
• [72]Stone GW,Witzenbichler B,Weisz G,et al.Platelet reactivity and clinical outcomes after coronary artery implantation of drugeluting stents(ADAPT-DES):a prospective multicentre registry study.Lancet,2013,382(9892):614-623.
• [73]Fox KA,Dabbous OH,Goldberg RJ,et al.Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome:prospective multinational observational study(GRACE).BMJ,2006,333(7578):1091.
• [74]Chew DP,Juergens C,French J,et al.An examination of clinical intuition in risk assessment among acute coronary syndromes patients:observations from a prospective multi-center international observational registry.Int J Cardiol,2014,171(2):209-216.
• [75]Li S,Liu H,Liu J.Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome.J Thromb Thrombolysis,2016,42(3):360-368.